Results for tag: "Ilaris"

Ilaris is a biologic drug used to treat a variety of immune disorders, including cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and gouty arthritis. It is a recombinant human interleukin-1 receptor antagonist (IL-1Ra) that works by blocking the action of interleukin-1, a protein involved in inflammation. Ilaris is administered as a subcutaneous injection and is available in both single-dose and multi-dose vials. The Ilaris market is a rapidly growing segment of the immune disorders drugs market. It is driven by the increasing prevalence of immune disorders, the availability of new treatments, and the increasing demand for personalized medicine. Ilaris is a promising treatment option for patients with immune disorders, as it has been shown to be effective in reducing symptoms and improving quality of life. Companies in the Ilaris market include Novartis, Pfizer, and Sanofi. Show Less Read more